MA-EXAGRID
4.4.2024 14:01:33 CEST | Business Wire | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution, today announced the appointment of Sam Elbeck as the new VP of Americas Sales and Channel Partners.
“I am looking forward to working with the ExaGrid sales teams throughout the Americas, and help ExaGrid accelerate its growth within the $6 billion backup storage market,” said Sam Elbeck. He will work with the local ExaGrid teams across the U.S., Canada, and Latin America, alongside each Area Vice President, to strengthen channel partnerships and build successful programs with leading reseller partners in each region.
Sam Elbeck recently joined ExaGrid after his position as VP of Sales and Partnerships Americas for Arcserve, and prior to that he was Senior Global Director of Sales for Digital Compliance and SaaS Backup at Veritas. Sam was also VP of Sales and Business Development for Globanet, and held sales and technical leadership roles at both Symantec and IBM.
“ExaGrid is continuing to expand, with sales teams in more than 30 countries, as well as 4,200 active customer installations in more than 80 countries,” said Bill Andrews, President and CEO of ExaGrid. “We are pleased to welcome Sam Elbeck who will lead the sales teams in the Americas, and work with them to grow our partnerships in the channel and bring our Tiered Backup Storage solution to more organizations.”
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The Repository Tier offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks.
ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, India, Israel, Italy, Japan, Mexico, Nordics, Poland, Portugal, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.
Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup storage in our customer success stories. ExaGrid is proud of our +81 NPS score!
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404887465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG’s MidOcean Energy Announces Initial Equity Raise of $1.2 billion Versus $1.0 billion Cover17.3.2026 08:26:00 CET | Press release
MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced an equity capital raise of more than $1.2 billion. This equity raise includes: a $500 million commitment from Idemitsu Kosan, a highly respected global energy company with a long-standing presence across the energy value chain; and additional commitments of $790 million from both new and existing investors. This represents a significant milestone in MidOcean’s capital formation program and reflects continued interest from both new and existing investors in the Company’s strategy to seek to build a diversified, resilient, long-life global LNG platform. There is significant further momentum from additional investors currently in documentation. MidOcean will continue to raise capital, with a cumulative target of up to $2 billion from new investors. The Company has received substantial interest from investors seeking long-term exposure to the LNG sector, supported
RS2 Launches “Beyond by RS2” to Power the Next Generation of European Fintech17.3.2026 08:00:00 CET | Press release
RS2, a Tier-1 global provider of payment processing infrastructure and technology solutions, today announced the launch of Beyond by RS2, a new digital payments brand designed to help fintech companies, platforms, and payment providers rapidly launch card issuing and payment acceptance services across Europe. Built on RS2’s globally proven BankWORKS platform, Beyond by RS2 offers fintechs a comprehensive sponsored issuer and acquiring program, enabling partners to issue cards and process payments without needing their own banking license or direct card scheme membership. The program leverages RS2’s Electronic Money Institution (EMI) license in Germany and its principal membership with Visa and Mastercard, allowing fintech partners to operate under RS2’s regulated infrastructure while maintaining their own customer experience and brand. “Beyond by RS2 represents a major step in our strategy to enable innovation in payments,” said Radi El Haj, CEO, RS2. “Fintechs today want to build powe
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay17.3.2026 07:00:00 CET | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Neurofilament light chain (NfL) in plasma and serum. “While our assay menu already features many powerful disease-specific biomarkers, NfL marks a major breakthrough: our first CE-marked blood test that empowers clinicians with insights across a wide range of neurological disorders,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “We are excited to bring this test to our customers, further expanding our comprehensive portfolio of fully automated neurological disease testing solutions on the LUMIPULSE G platform. We continue to partner with organizations and clinical experts across the wor
H2SITE Appoints Javier Cavada as New Chairman of the Board of Directors17.3.2026 07:00:00 CET | Press release
H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316654723/en/ With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, building high-performance organisations, and scaling large-scale energy platforms. He currently serves as President and Chief Executive Officer of Mitsubishi Power EMEA. His track record also includes serving as CEO and President of Highview Power, as well as spending 17 years at Wärtsilä Corporation, where he held senior executive roles including President of the Energy division and a member of the global Exec
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies17.3.2026 07:00:00 CET | Press release
Galderma will present nine posters spanning its full aesthetics portfolio at AMWC 2026, highlighting the regenerative benefits of Sculptra®, the long-lasting efficacy of Restylane®, and the advanced clinical performance of Relfydess® (RelabotulinumtoxinA) 1-9 The data reinforce Galderma’s future-focused approach to innovation, addressing emerging patient needs from menopause‑related skin changes to rising interest in body injectables and regenerative treatments A series of symposia and Masterclasses will further highlight Galderma’s leadership in aesthetics, showcasing how the portfolio supports complex patient profiles and evolving global trends Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra, R
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom